|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | DETAILED DRUG INFORMATION OF ADO TRASTUZUMAB EMTANSINE AND ITS THERAPEUTIC USES. |
| Authors Name: | Vedant Sheth , Akansha Pandit , Honey Desai , Dhaval Chauhan , SP Srinivas Nayak |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_205434
|
| Published Paper Id: | IJNRD2309198 |
| Published In: | Volume 8 Issue 9, September-2023 |
| DOI: | |
| Abstract: | Ado trastuzumab emtansine, a medication used to treat breast cancer that is HER2-positive, is discussed in great detail in this review article. Ado-trastuzumab emtansine, sometimes referred to as T-DM1, is an amalgamation of the cytotoxic DM1 medication and the anti-HER2 medicine trastuzumab. This medication works by delivering DM1 to cancer cells via attaching on the HER 2 receptor on cancer cells. Cell cycle interruption and death of cells (apoptosis) are the results of this. It has been demonstrated that ado-trastuzumab emtansine is successful in treating HER 2-positive, early-stage breast cancer. But it can also result in negative side effects like discomfort, exhaustion, and even heart damage. This medication is administered intravenously and is metabolised in the liver. It has a half-life of roughly 70 hours and is eliminated through the urine and stool.Ado trastuzumab emtansine may interact with other medications and may require dose adjustment. In general, this is a good way to treat HER2-positive breast cancer. |
| Keywords: | T-DM1, HER2-positive breast cancer, targeted treatment, combination therapy,clinical evidence,trastuzumab-emtansine. |
| Cite Article: | "DETAILED DRUG INFORMATION OF ADO TRASTUZUMAB EMTANSINE AND ITS THERAPEUTIC USES.", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 9, page no.b855-b861, September-2023, Available :http://www.ijnrd.org/papers/IJNRD2309198.pdf |
| Downloads: | 000118759 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2309198 Registration ID: 205434 Published In: Volume 8 Issue 9, September-2023 DOI (Digital Object Identifier): Page No: b855-b861 Country: Vadodara, Gujarat, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2309198 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2309198 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn